jeffrey sharman, md, explains how we should be thinking about btk inhibitors in the treatment of cll
Published 4 years ago • 43 plays • Length 2:37
Download video MP4
Download video MP3
Similar videos
-
0:48
jeffrey sharman, md, on the benefits of zanubrutinib as compared to other btk inhibitors
-
2:14
jeff sharman, md, on how important the cll-14 study is in determining cll treatment strategies
-
1:11
ryan lynch, md, on how physicians should be thinking about btk inhibitors in the treatment of cll
-
1:44
chaitra ujjani, md, considers how physicians should be thinking about btk inhibitors in cll
-
1:57
geoffrey oxnard, md, explains how genomic markers can guide treatment in pd-l1 positive nsclc
-
1:52
jeffrey sharman, md, shares updates from the cll14 study presented at ash 2019
-
41:01
minimally invasive surgery: when and why to use it - jeffrey s. roh, md, mba
-
2:19
jeffrey weber, md, phd: factors to consider when determining treatment
-
57:16
sir-rfs webinar (3/10/2016): management of hepatocellular carcinoma: how i do it
-
30:59
vaccines update, nejm weighs in
-
1:28
jeffrey weber, md, phd: factors to consider when determining treatments
-
10:50
md lesson 3.1
-
1:01
btk inhibitors: toxicity, resistance, and combinations
-
21:21
inflammasome activation in acute covid-19 - judy lieberman, md, phd
-
1:05
chaitra ujjani, md, considers the ideal patient profile for zanubrutinib in rr-mcl
-
2:10
genomic factors underlying resistance to immunotherapy in newly diagnosed multiple myeloma
-
1:46
dr. steven sherman discusses mek inhibitors for thyroid cancer
-
45:27
rsm covid-19 series | episode 43: long covid: understanding the shadow of the virus
-
56:36
nicholson lecture 2017: jeffrey m friedman
Clip.africa.com - Privacy-policy